A rapid on-line publication of the first randomised controlled trial of low dose naltrexone in MS in the Annals of Neurology has been reported prior to hard copy publication.
The study randomised 80 people with MS to receive LDN or placebo in a cross-over study where people took the LDN or placebo for eight weeks, then swapped to the other study drug.
This appears to be the first drug trial in MS that was not funded by the pharmaceutical industry, but by the participants themselves.
The researchers found significant improvements for LDN over placebo in several mental health quality of life measures.
This appears to be the beginning of formal research into LDN in MS, and further trials are eagerly awaited by the research community.